- Home
- GITS vs NCNA Comparison
GITS vs NCNA Comparison
Compare GITS & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GITS
- NCNA
- Stock Information
- Founded
- GITS 2018
- NCNA 1997
- Country
- GITS South Korea
- NCNA United Kingdom
- Employees
- GITS N/A
- NCNA N/A
- Industry
- GITS
- NCNA Biotechnology: Pharmaceutical Preparations
- Sector
- GITS
- NCNA Health Care
- Exchange
- GITS Nasdaq
- NCNA Nasdaq
- Market Cap
- GITS 7.2M
- NCNA 7.6M
- IPO Year
- GITS N/A
- NCNA 2017
- Fundamental
- Price
- GITS $1.80
- NCNA $5.07
- Analyst Decision
- GITS
- NCNA
- Analyst Count
- GITS 0
- NCNA 0
- Target Price
- GITS N/A
- NCNA N/A
- AVG Volume (30 Days)
- GITS 153.8K
- NCNA 648.7K
- Earning Date
- GITS 11-19-2025
- NCNA 11-24-2025
- Dividend Yield
- GITS N/A
- NCNA N/A
- EPS Growth
- GITS N/A
- NCNA N/A
- EPS
- GITS N/A
- NCNA N/A
- Revenue
- GITS $29.00
- NCNA N/A
- Revenue This Year
- GITS N/A
- NCNA N/A
- Revenue Next Year
- GITS N/A
- NCNA N/A
- P/E Ratio
- GITS N/A
- NCNA N/A
- Revenue Growth
- GITS N/A
- NCNA N/A
- 52 Week Low
- GITS $0.87
- NCNA $2.78
- 52 Week High
- GITS $9.78
- NCNA $407.70
- Technical
- Relative Strength Index (RSI)
- GITS 33.44
- NCNA 52.98
- Support Level
- GITS $2.00
- NCNA $5.00
- Resistance Level
- GITS $2.33
- NCNA $6.10
- Average True Range (ATR)
- GITS 0.16
- NCNA 0.82
- MACD
- GITS -0.03
- NCNA -0.07
- Stochastic Oscillator
- GITS 30.21
- NCNA 39.77
About GITS Global Interactive Technologies Inc. Common Stock
Global Interactive Technologies Inc, formerly Hanryu Holdings Inc is the creator of the engaging social media platform, FANTOO. Through FANTOO, it provides a multi-media platform for its users to interact with other like-minded users, share their appreciation of various types of entertainment and cultures, create their content, enjoy content, and engage in commerce.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.